3M acquires Acolyte Biomedica

3M has acquired Acolyte Biomedica, a Salisbury, UK-based provider of an automated microbial detection platform that aids in the detection, diagnosis, and treatment of infectious diseases.



According to 3M, early detection of dangerous microbes is becoming more important as multiple resistant bacteria strains become more prevalent. Acolyte Biomedica helps hospitals control high-risk infections through improved screening and targeted treatment of methicillin-resistant Staphylococcus aureus (MRSA), a type of bacteria that is resistant to certain antibiotics and occurs most frequently in hospital patients who have weakened immune systems.



Acolyte Biomedica brings to 3M’s infection prevention platform a pipeline of rapid culture-based screening tests for microbes, such as MRSA and vancomycin-resistant enterococcus (VRE), that simplify the diagnostic process by automating traditional culture methodology resulting in reliable confirmed ‘negatives’ in hours rather than days.



The addition of Acolyte Biomedica allows 3M to expand more quickly into the emerging market of infection prevention diagnostics, especially in Europe where Acolyte Biomedica has commercialised product for MRSA.